This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, B. Articles by Hood, L. Search for Related Content PubMed PubMed Citation Articles by Lin, B. Articles by Hood, L.

Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease

¹ Institute for Systems Biology; ² Department of Urology, University of Washington, Seattle, Washington; and ³ Lynx Therapeutics, Inc., Hayward, California

Requests for reprints: Biaoyang Lin, Institute for Systems Biology, 1441 North 34th Street, Seattle, WA 98103. Phone: 206-732-1297; Fax: 206-732-1299; E-mail: blin{at}systemsbiology.org.

Prostate cancer is initially responsive to androgen ablation therapy and progresses to androgen-unresponsive states that are refractory to treatment. The mechanism of this transition is unknown. A systems approach to disease begins with the quantitative delineation of the informational elements (mRNAs and proteins) in various disease states. We employed two recently developed high-throughput technologies, massively parallel signature sequencing (MPSS) and isotope-coded affinity tag, to gain a comprehensive picture of the changes in mRNA levels and more restricted analysis of protein levels, respectively, during the transition from androgen-dependent LNCaP (model for early-stage prostate cancer) to androgen-independent CL1 cells (model for late-stage prostate cancer). We sequenced >5 million MPSS signatures, obtained >142,000 tandem mass spectra, and built comprehensive MPSS and proteomic databases. The integrated mRNA and protein expression data revealed underlying functional differences between androgen-dependent and androgen-independent prostate cancer cells. The high sensitivity of MPSS enabled us to identify virtually all of the expressed transcripts and to quantify the changes in gene expression between these two cell states, including functionally important low-abundance mRNAs, such as those encoding transcription factors and signal transduction molecules. These data enable us to map the differences onto extant physiologic networks, creating perturbation networks that reflect prostate cancer progression. We found 37 BioCarta and 14 Kyoto Encyclopedia of Genes and Genomes pathways that are up-regulated and 23 BioCarta and 22 Kyoto Encyclopedia of Genes and Genomes pathways that are down-regulated in LNCaP cells versus CL1 cells. Our efforts represent a significant step toward a systems approach to understanding prostate cancer progression.

This article has been cited by other articles:

				N. Gehlenborg, D. Hwang, I. Y. Lee, H. Yoo, D. Baxter, B. Petritis, R. Pitstick, B. Marzolf, S. J. DeArmond, G. A. Carlson, et al. The Prion Disease Database: a comprehensive transcriptome resource for systems biology research in prion diseases Database, September 17, 2009; 2009(0): bap011 - bap011. [Abstract] [Full Text] [PDF]

				L. Hood, L. Rowen, D. J. Galas, and J. D. Aitchison Systems biology at the Institute for Systems Biology Brief Funct Genomic Proteomic, July 1, 2008; 7(4): 239 - 248. [Abstract] [Full Text] [PDF]

				B. Lin, A. G. Utleg, K. Gravdal, J. T. White, O. J. Halvorsen, W. Lu, L. D. True, R. Vessella, P. H. Lange, P. S. Nelson, et al. WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence Clin. Cancer Res., March 1, 2008; 14(5): 1397 - 1406. [Abstract] [Full Text] [PDF]

				L. C. Tu, X. Yan, L. Hood, and B. Lin Proteomics Analysis of the Interactome of N-myc Downstream Regulated Gene 1 and Its Interactions with the Androgen Response Program in Prostate Cancer Cells Mol. Cell. Proteomics, April 1, 2007; 6(4): 575 - 588. [Abstract] [Full Text] [PDF]

				G. Sardana, J. Marshall, and E. P. Diamandis Discovery of Candidate Tumor Markers for Prostate Cancer via Proteomic Analysis of Cell Culture-Conditioned Medium Clin. Chem., March 1, 2007; 53(3): 429 - 437. [Abstract] [Full Text] [PDF]

				D. F. Moore, O. V. Krokhin, R. C. Beavis, M. Ries, C. Robinson, E. Goldin, R. O. Brady, J. A. Wilkins, and R. Schiffmann Proteomics of specific treatment-related alterations in Fabry disease: A strategy to identify biological abnormalities PNAS, February 20, 2007; 104(8): 2873 - 2878. [Abstract] [Full Text] [PDF]

				A. Ng, B. Bursteinas, Q. Gao, E. Mollison, and M. Zvelebil pSTIING: a 'systems' approach towards integrating signalling pathways, interaction and transcriptional regulatory networks in inflammation and cancer Nucleic Acids Res., January 1, 2006; 34(suppl_1): D527 - D534. [Abstract] [Full Text] [PDF]

				S. Fitter and R. James Deconvolution of a Complex Target Using DNA Aptamers J. Biol. Chem., October 7, 2005; 280(40): 34193 - 34201. [Abstract] [Full Text] [PDF]

				E. Michelini, M. Magliulo, P. Leskinen, M. Virta, M. Karp, and A. Roda Recombinant Cell-Based Bioluminescence Assay for Androgen Bioactivity Determination in Clinical Samples Clin. Chem., October 1, 2005; 51(10): 1995 - 1998. [Full Text] [PDF]